Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.25    0.00 (0.00%)
Bid:
6.00
Ask:
6.50
Spread: 0.50 (8.333%)
Market Cap: £6.46m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Trading Update

8 Feb 2012 07:00

CERES MEDIA INTERNATIONAL PLC ("Ceres", "the Company" or "the Group") Trading update

Further to the announcement made 19 December 2011, the Company has now resolved the technical issues associated with the production of its TierraFilm range and has taken delivery of stock of this product and, upon receipt of an order, can be immediately delivered. The TierraFilm products are currently being trialled by distributors, printers and end users and the feedback received by the Company from the trials has been positive.

TierraFilm products are designed as an environmental alternative to the coated paper or oil based materials typically used in the print industry. They are manufactured using Sustainable Forestry InitiativeTM (SFI) certified raw materials and can be disposed of in existing biodegradation, composting or Energy From Waste systems removing the need to landfill.

Delays in scaling up production and bringing TierraFilm to the market together with the slower than anticipated take-up of Gossyp and Chorus products, as previously announced, have had a consequential impact on the Company's working capital position, which the board is monitoring closely. The board has also taken action to reduce the cost base of the Company in order to conserve its cash position.

The sales of Chorus and Gossyp, the Company's other principal products, continue to be significantly below the board's expectations and the Company is continuing to refocus its sales strategy in relation to these products.

A further update will be made in due course.

For further information, please contact:

Ceres Media International PLC Tel: 020 3178 5622 Alex Dowdeswell Leslie Barber Nominated Adviser Tel: 020 7148 7900 Cairn Financial Advisers LLP Jo Turner / Liam Murray Broker Tel: 020 3002 2070 First Columbus LLP

Chris Crawford / Kelly Gardiner Financial PR Tel: 020 7556 1063 De Facto Financial

Mike Wort / Anna Dunphy

XLON
Date   Source Headline
28th May 20197:00 amRNSAppointment of CEO of ProBiotix Health
22nd May 20197:00 amRNSGoFigure® distribution agreement for Poland
20th May 20197:00 amRNSLicense agreement for LPLDL®
17th May 20197:00 amRNSNotice of AGM
14th May 20197:00 amRNSDistribution Agreement for SlimBiome® in Thailand
7th May 20197:00 amRNSLicense agreement for LPLDL®
2nd May 20197:00 amRNSInvestor evening
1st May 20197:00 amRNSSlimBiome launch to EU market at Vitafoods Europe
29th Apr 20197:00 amRNSFinal Results
24th Apr 20197:00 amRNSSlimBiome® Medical launches in UK market
11th Apr 20197:00 amRNSSlimBiome® receives approval from FSSAI in India
9th Apr 20197:00 amRNSSlimBiome® Medical agreement for Bulgaria
27th Mar 20193:18 pmRNSGrant of Options
27th Mar 20197:43 amRNSSweetBiotix®: Scientific and commercial update
27th Mar 20197:00 amRNSSweetBiotix®: Scientific and commercial update
25th Mar 201911:00 amRNSPrice Monitoring Extension
20th Mar 20197:00 amRNSExclusive distribution agreement for SlimBiome®
15th Mar 20197:00 amRNSExtension of term and territories for LPLDL®
13th Mar 20193:42 pmRNSExercise of Warrants
21st Feb 20197:00 amRNSLPLDL® determined GRAS by an Expert Panel in US
20th Feb 20197:00 amRNSPresentations at ProBiota - 2019
13th Feb 20197:00 amRNSTrading Statement
11th Feb 20197:00 amRNSDistribution agreement for LPLDL® in Japan
7th Feb 20197:00 amRNSSupply agreement for LPLDL® in the Baltic States
18th Jan 20191:56 pmRNSExercise of Warrants
11th Jan 20197:00 amRNSDirector Appointment
9th Jan 20197:00 amRNSDistribution agreement for CholBiome
7th Jan 20197:00 amRNSManufacturing agreement for SlimBiome®
17th Dec 20187:00 amRNSDirectorate Change
14th Dec 20187:00 amRNSIssue of Convertible Loan Notes by ProBiotix
5th Dec 20182:58 pmRNSHolding(s) in Company
4th Dec 20187:00 amRNSSlImBiome® Medical agreement for Greece and Cyprus
29th Nov 20187:00 amRNSSlimBiome Medical manufacturing agreement
27th Nov 20187:00 amRNSSlimBiome® granted medical device status & CE mark
22nd Nov 20187:00 amRNSCholBiome® agreement for Greece and Cyprus
11th Oct 20187:00 amRNSDirector's Dealing
9th Oct 20187:00 amRNSLPLDL® US manufacturing and supply agreement
8th Oct 20187:00 amRNSExercise of Options & Director's Dealing
3rd Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
1st Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
26th Sep 20187:00 amRNSDistribution agreement for CholBiome®
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 20187:00 amRNSFormation of ProBiotix Health Limited
10th Sep 20187:00 amRNSDirector Appointment
10th Sep 20187:00 amRNSLicence agreement with Bened Biomedical
10th Sep 20187:00 amRNSExercise of Warrants and Issue of Equity
4th Sep 20187:00 amRNSOptiBiotix signs US pharmaceutical deal
30th Aug 20187:00 amRNSHalf-year Report
6th Aug 20187:00 amRNSProposed directorate change
31st Jul 201810:04 amRNSDirector's dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.